CelluTarget · Multifocal Motor Neuropathy · Treatments
✓ Standard of Care

Injectable PCSK9 inhibitors (evolocumab, alirocumab)

Amgen ↗
1
Evidence entries
0
Clinical trials
1
High-confidence findings
Overview
Treatment Details
Mechanism of Action
Monoclonal antibodies that bind and inhibit PCSK9, preventing it from degrading LDL receptors on hepatocytes. This increases LDL receptor recycling back to the cell surface, dramatically reducing circulating LDL-C by 50–60% on top of statin therapy. FDA-approved for ASCVD secondary prevention and familial hypercholesterolemia.
Dosing Notes
Evolocumab (Repatha): 140 mg SC every 2 weeks or 420 mg monthly. Alirocumab (Praluent): 75–150 mg SC every 2 weeks.
Treatment Type
pharmaceutical
Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
High ConfidenceSupported by multiple robust studies or regulatory approval
Evolocumab (FOURIER) and alirocumab (ODYSSEY OUTCOMES) both demonstrated significant reductions in MACE in large Phase 3 outcomes trials. Evolocumab reduced the primary composite endpoint by 15%; alirocumab by 15%. Both FDA-approved for ASCVD secondary prevention and familial hypercholesterolemia.
Verified Jul 2026
Peer Reviewed
The evolving therapeutic landscape of PCSK9 inhibition (Atherosclerosis journal, 2026)
Published February 2026
View source ↗
Clinical Trials
Linked Trials
No clinical trials linked to this treatment yet.
Injectable PCSK9 inhibitors (evolocumab, alirocumab) for MMN — Evidence & Clinical Trials | CelluTarget